| 发明名称 | Anti-CD26 antibodies and uses thereof | ||
| 摘要 | The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts. | ||
| 申请公布号 | US9376498(B2) | 申请公布日期 | 2016.06.28 |
| 申请号 | US201414184241 | 申请日期 | 2014.02.19 |
| 申请人 | ADIENNE S.A. | 发明人 | Di Naro Antonio Francesco |
| 分类号 | C07K16/28;A61K39/395;C07K16/40;A61K39/00 | 主分类号 | C07K16/28 |
| 代理机构 | Sterne, Kessler, Goldstein & Fox P.L.L.C. | 代理人 | Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| 主权项 | 1. An isolated monoclonal antibody that specifically binds human CD26 comprising a heavy chain variable region and a light chain variable region, wherein a) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO: 133, a VH CDR2 comprising the sequence of SEQ ID NO: 134, and a VH CDR3 comprising the sequence of SEQ ID NO: 1; and b) the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO: 129 or 131, a VL CDR2 comprising the sequence of SEQ ID NO: 130 or 132, and a VL CDR3 comprising the sequence of SEQ ID NO: 2 or 3. | ||
| 地址 | Lugano CH | ||